Propranolol and breast cancer—a work in progress

Propranolol and breast cancer—a work in progress

The non-selective beta-blocker propranolol is a leading candidate for repurposing as a novel anti-cancer agent. Emerging evidence, including human data, suggests that there are multiple mechanisms of action particularly relevant to breast cancer. This editorial reviews a number of recent studies that show it has anti-metastatic activity that warrants clinical investigation, including investigation as a potential perioperative therapy in breast cancer.

pantziarka_2018_propranolol_and_breast_cancer-a_work_in_progress.pdf